MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
Lightouch Medical, Bryn Athyn, Pa.
Lightouch Medical is developing a device that takes blood glucose measurements through the skin of the finger.
Officers
Donald Schmucker, President & CEO
George Shaheen, VP
Joseph Chaiken, CSO
Paul Shaheen, Co-Founder & Director
Ralph Brill, Consultant
Product
Lightouch Medical has spent the past 10 years developing and patenting (nine patents issued) a device that reads true blood glucose measurements through the skin of a person’s finger, non-invasively – no pricking, no blood. Lightouch’s platform technology uses Raman spectroscopy and tissue modulation to accurately measure blood glucose content. An operating beta unit is in the company’s laboratory. Upon receipt of funding it will take about year to have a test unit ready for FDA review. Lightouch’s first products will be geared to the 20 million diabetics in the U.S. and 100 million internationally – a $5 billion market. In line with today’s remote monitoring ideals, the Lightouch units can send the patient’s data over the Internet to their doctor and clinic and likewise their doctors can send messages and menu change data to them. The Lightouch technology can provide for real time molecule specific observations in the blood non-invasively including the measurement of hematocrit and other analytes including cholesterol, triglycerides and lactic acid. Other high+value uses for the Lightouch technology might be in emergency rooms and battlefields.
The Lightouch Clinic Unit is to be the first commercially available product. This lap-top sized unit is geared for clinics, doctors’ offices and schools. The PDA sized Personal Unit will be ready about 18 months thereafter with additional financing. All units will be Internet-ready.